EnCor Biotechnology

EnCor Biotechnology is an American biotechnology company based in Gainesville, Florida, that develops and manufactures monoclonal and polyclonal antibodies and related research reagents. Its principal specialization is the study of neural proteins, nervous-system injury, neurodegeneration, and associated biomarkers. The company supplies products primarily to academic, biomedical, pharmaceutical, and diagnostic research laboratories, while also supplying reagents to larger life-science distribution and reagent companies. The company was founded at the end of 1999 as a spin-off from the University of Florida. Its origins lay in the research of Gerry Shaw, a British scientist who worked in the University of Florida's neuroscience program and later became a professor emeritus. During Shaw's academic career in the 1990s, antibodies produced in his laboratory for research purposes were licensed to outside companies. EnCor was established to commercialize antibodies generated by Shaw's laboratory while making them available at comparatively accessible prices. In late 2001, EnCor moved into laboratory space at the Sid Martin Biotechnology Incubator, a University of Florida-associated facility intended to help commercialize university-generated intellectual property. The company subsequently expanded its antibody-development activities, undertaking the production, characterization, documentation, manufacturing, and quality-control work needed to turn laboratory reagents into commercial products. It became profitable during this period and relocated to Gainesville in 2006. EnCor's product portfolio focuses heavily on antibodies used in immunocytochemistry and western blotting. Its reagents are also used in immunoprecipitation, ELISA, diagnostic histopathology, and the measurement or investigation of protein biomarkers. The company has collaborated with basic scientists and clinicians on peer-reviewed research involving biomarkers of nervous-system damage and degeneration. Areas associated with its research include neurofilament proteins, UCHL1, alpha-synuclein, and other proteins relevant to Parkinson's disease and related neurological conditions. A notable area of work concerns phosphorylated neurofilament heavy chain, commonly called pNF-H, a form of the NEFH protein studied as a marker of axonal injury. EnCor has also developed assays and antibodies involving UCHL1 and alpha-synuclein. In collaboration with University of Florida researchers, the company described a class of neurofilament light-chain antibodies in work published in the early 2020s. Some of these reagents recognize epitopes that are concealed in healthy neurons but become exposed during neuronal degeneration. These degeneration-specific antibodies were termed DegenoTag reagents, while another antibody class recognized neurofilaments in healthy neurons but not degenerating or degenerated neurons. By 2022, the company reported a product line of more than 250 items. Its antibodies are principally research-use reagents, although some have applications in histopathology and biomarker studies with possible future clinical relevance. EnCor products have been supplied directly to research laboratories and through companies including Abcam, BioLegend, Thermo Fisher Scientific, EMD Millipore, and Bio-Techne. The company is also recognized for detailed cell, tissue, and western-blot images used in scientific publications, teaching materials, posters, advertising, and other research communications. EnCor's business model combines antibody commercialization, custom scientific reagent development, and collaboration with academic and clinical researchers. Its identity remains closely tied to neuroscience-focused reagent quality and the translation of university-originated research into products for laboratories investigating neural structure, injury, and disease.

EnCor Biotechnology emerged from neuroscience research conducted at the University of Florida by Gerry Shaw. During the 1990s, antibodies developed in Shaw's laboratory for experimental use were licensed to outside companies. This experience demonstrated that university research reagents could be commercialized, but it also created an opportunity for a dedicated company to market the laboratory's antibodies more directly and at lower prices. EnCor was founded at the end of 1999 as a University of Florida spin-off for that purpose. The company initially concentrated on bringing existing laboratory antibodies to the research market. Its activities later expanded beyond commercialization of previously developed reagents. In late 2001, EnCor rented laboratory space at the Sid Martin Biotechnology Incubator, a facility associated with the commercialization of intellectual property originating at the University of Florida. The move gave the company a setting in which it could develop, characterize, document, manufacture, and quality-control an increasing number of novel antibodies. As its technical capabilities and catalog grew, EnCor became profitable and moved to Gainesville in 2006. Its core business remained the development of antibodies against proteins relevant to the nervous system. The company built a product portfolio aimed primarily at research applications, especially immunocytochemistry and western blotting, while also supporting immunoprecipitation, ELISA, histopathology, and biomarker investigations. EnCor's scientific work has been closely connected with collaborative research. The company has worked with academic scientists and clinicians on peer-reviewed studies of plasma, serum, and cerebrospinal-fluid biomarkers associated with nervous-system injury and degeneration. One important target has been phosphorylated neurofilament heavy chain, or pNF-H, a form of the NEFH protein investigated as a marker of axonal damage. Other work involved UCHL1 and alpha-synuclein, proteins relevant to brain biology, Parkinson's disease, and other neurological disorders. In the early 2020s, EnCor collaborated with University of Florida researchers on a new class of antibodies directed at neurofilament light chain, also known as NF-L or NEFL. The reported antibodies showed different patterns of recognition. One class bound epitopes hidden in healthy neurons and neuronal processes but exposed during degeneration. Another class recognized neurofilaments in healthy neurons and processes but did not recognize degenerating or degenerated structures. The degeneration-selective reagents were given the name DegenoTag and were presented as potentially useful tools for research into neurodegenerative disease. By 2022, EnCor's catalog had grown to more than 250 products. Although most were intended for research use, some reagents were also used in diagnostic histopathology and in studies measuring protein biomarkers. The company supplied laboratories directly and supplied products or reagents to established life-science companies, including Abcam, BioLegend, Thermo Fisher Scientific, EMD Millipore, and Bio-Techne. The company has also developed a reputation for the quality and usefulness of its experimental images. Cell, tissue, and western-blot images associated with EnCor reagents have been used in scientific articles, books, posters, teaching, advertising, and other forms of research communication. Overall, EnCor's history reflects a focused biotechnology model: converting university neuroscience research into specialized antibody products while continuing to work with researchers on tools for studying neural proteins, axonal injury, and neurodegeneration.

1. 2023Uman-type neurofilament light antibodies published in Brain Communications

   Peer-reviewed research reported the effectiveness of Uman-type neurofilament light antibodies for imaging neurodegeneration.

   Source
2. 2022DegenoTag neurofilament light-chain antibodies described

   EnCor and University of Florida researchers described antibody classes with differential recognition of healthy and degenerating neuronal neurofilament light-chain structures.

   Source
3. 2022Product catalog exceeds 250 items

   The company's product line had grown to more than 250 antibody and related reagent products, mainly serving research applications.

   Source
4. 2006Relocation to Gainesville

   After becoming profitable and increasing its reagent-development activities, EnCor relocated to Gainesville, Florida.

   Source
5. 2005Research reports pNF-H as a serum biomarker of axonal injury

   A publication involving Gerry Shaw and collaborators examined hyperphosphorylated neurofilament NF-H as a blood-based indicator of axonal injury.

   Source
6. 2001Laboratory operations begin at the Sid Martin Biotechnology Incubator

   EnCor rented laboratory space at the Sid Martin Biotechnology Incubator and expanded its work on developing, characterizing, manufacturing, and documenting new antibodies.

   Source
7. 1999Company founded as a University of Florida spin-off

   EnCor Biotechnology was established to commercialize antibody reagents developed in Gerry Shaw's neuroscience laboratory and offer them to researchers at relatively low prices.

   Source

A specialist neuroscience-reagent company focused on high-quality antibodies and assays for neural proteins, axonal injury, neurodegeneration, and biomarker research.

• Neurofilament antibodiesResearch antibodies

  Antibodies directed at neurofilament proteins, including neurofilament heavy chain and neurofilament light chain. These reagents support studies of neuronal structure, axonal injury, degeneration, and disease-related changes using techniques such as immunocytochemistry, western blotting, immunoprecipitation, and related assays.

• pNF-H reagentsNeurodegeneration biomarker reagents

  Reagents targeting phosphorylated neurofilament heavy chain, commonly called pNF-H. The target has been investigated as a biomarker of axonal injury and nervous-system damage in biological samples including serum and cerebrospinal fluid.

• DegenoTag reagentsNeurodegeneration research antibodies2022

  A class of neurofilament light-chain antibodies reported to recognize epitopes exposed during neuronal degeneration but concealed in healthy neurons and their processes. The reagents are intended to help researchers visualize and investigate neurodegenerative changes.

• UCHL1 reagentsNeural-protein antibodies and assays

  Antibody and assay reagents directed at UCHL1, a major brain protein examined in research on nervous-system biology, neuronal injury, and neurological disease. EnCor has described assay work involving UCHL1 in collaboration with researchers.

• Alpha-synuclein reagentsNeural-protein antibodies and assays

  Reagents targeting alpha-synuclein, a protein strongly associated with Parkinson's disease and other neurodegenerative research. Products support laboratory investigation of protein localization, abundance, and disease-related biology.

• 2022Develop degeneration-selective neurofilament light-chain reagentsProduct launch

  Researchers sought tools that could distinguish healthy neuronal neurofilament structures from those exposed or altered during degeneration.

  What changed. EnCor and University of Florida collaborators described distinct antibody classes against neurofilament light chain, including the degeneration-focused DegenoTag class.

  Aftermath. The reagents were positioned as potentially useful tools for imaging and studying neurodegeneration, with related work later published in Brain Communications.

  Source
• 2001Expand laboratory operations through an incubator facilityStrategy

  EnCor needed laboratory capacity to increase the number of novel antibodies it could develop and commercialize.

  What changed. The company rented laboratory space at the Sid Martin Biotechnology Incubator.

  Aftermath. The company increased its capabilities in antibody development, documentation, manufacturing, and quality control and subsequently became profitable.

  Source
• 1999Commercialize university-developed antibodies through a dedicated spin-offStrategy

  Antibodies created in Gerry Shaw's University of Florida laboratory had already been licensed for commercial sale. EnCor was formed to market laboratory-generated reagents more directly and at lower prices.

  What changed. The founders established EnCor Biotechnology as a separate company focused on antibody commercialization and later product development.

  Aftermath. The company expanded from marketing existing reagents into developing, characterizing, manufacturing, and quality-controlling a broader neuroscience antibody portfolio.

  Source

• 2023Neurofilament light-chain antibody work published in Brain Communications

  A peer-reviewed article described the use of Uman-type neurofilament light antibodies for imaging neurodegeneration.

  Product launch
  Source
• 2022EnCor researchers describe degeneration-focused neurofilament light-chain antibodies

  EnCor and University of Florida researchers reported antibody classes that distinguish neurofilament light-chain structures associated with healthy and degenerating neurons.

  Product launchProduct generation
  Source
• 2006EnCor relocates to Gainesville

  After expanding its reagent-development and manufacturing activity, EnCor relocated to Gainesville, Florida.

  Other
  Source
• 2001EnCor moves into the Sid Martin Biotechnology Incubator

  The company rented laboratory space at the Sid Martin Biotechnology Incubator, supporting the development and commercialization of university-originated antibody technology.

  Other
  Source
• 1999EnCor Biotechnology established as a University of Florida spin-off

  EnCor Biotechnology was formed to commercialize antibody reagents developed in Gerry Shaw's University of Florida neuroscience laboratory.

  Other
  Source

1. EnCor Biotechnology